SCHEMBL5865872

SCHEMBL5865872

O=c1cc(C(F)(F)F)c2cc(S(=O)(=O)N3CCN(c4ccccc4)CC3)ccc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
BLM P54132 1/20 0.60
MAPT P10636 5/20 0.58
AR P10275 1/20 0.57
HTT P42858 2/20 0.56
LMNA P02545 3/20 0.54
HPGD P15428 3/20 0.50
ALDH1A1 P00352 2/20 0.50
HSD11B1 P28845 1/20 0.50
GAA P10253 2/20 0.49
HSD17B10 Q99714 3/20 0.48
USP2 O75604 2/20 0.48
KDM4E B2RXH2 2/20 0.48
PTPN7 P35236 1/20 0.48
PKM P14618 1/20 0.47
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865898 0.90 AR (0.55) POLBMEN1KMT2ABLMMAPT
SCHEMBL5865930 0.85 AR (0.58) ARHTTGAAKDM4E
SCHEMBL5865922 0.85 AR (0.62) ARHTTGAAKDM4E
SCHEMBL5865886 0.85 MEN1 (0.66) POLBMEN1KMT2AMAPTAR
SCHEMBL5865880 0.84 AR (0.60) ARHTTGAAKDM4E
SCHEMBL5865849 0.84 AR (0.60) ARHTTGAAKDM4E
SCHEMBL5865857 0.84 AR (0.60) ARHTTGAAKDM4E
SCHEMBL5865847 0.82 AR (0.49) AR
SCHEMBL5865909 0.81 KDM4E (0.67) POLBMEN1KMT2AARHTT
SCHEMBL5865931 0.80 KDM4E (0.59) POLBMEN1KMT2AMAPTAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064207-B2 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives, useful for treating alopecia, acne and oily skin WARNER LAMBERT COMPANY LLC (US) 2006-06-20 US claimed
US-20050085467-A1 Androgen receptor antagonists DU DANIEL Y (US) 2005-04-21 US claimed
US-7064207-B2 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives, useful for treating alopecia, acne and oily skin WARNER LAMBERT COMPANY LLC (US) 2006-06-20 US disclosed
EP-1587804-A1 ANDROGEN RECEPTOR ANTAGONISTS Warner-Lambert Company LLC (US) 2005-10-26 EP disclosed
US-6893670-B2 Cheese ripening process DANISCO (UK LTD) (GB) 2005-05-17 US disclosed
US-20050085467-A1 Androgen receptor antagonists DU DANIEL Y (US) 2005-04-21 US disclosed
EP-1091652-B1 CHEESE RIPENING PROCESS DANISCO UK LTD (GB) 2005-03-30 EP disclosed
WO-2004065379-A1 ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-08-05 WO disclosed
US-20030180429-A1 Cheese ripening process DUPONT NUTRITION BIOSCIENCES APS (DK) 2003-09-25 US disclosed
US-20010024667-A1 Cheese ripening process DUPONT NUTRITION BIOSCIENCES APS (DK) 2001-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085467-A1 Androgen receptor antagonists AR, NR5A1, ESRRB POLB 3750/4885MEN1 3029/4885KMT2A 1126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.